Therapy Takes BiTE Out of Aggressive Lymphomas

(MedPage Today) -- Most patients with heavily treated relapsed/refractory B-cell lymphomas responded to a bispecific T-cell-engaging (BiTE) antibody following obinutuzumab (Gazyva) pretreatment, according to preliminary clinical data.
Across the...